“No decision about me without me” in the context of cancer multidisciplinary team meetings: a qualitative interview study by Cath Taylor et al.
Taylor et al. BMC Health Services Research 2014, 14:488
http://www.biomedcentral.com/1472-6963/14/488RESEARCH ARTICLE Open Access“No decision about me without me” in the
context of cancer multidisciplinary team
meetings: a qualitative interview study
Cath Taylor1*, Jennifer Finnegan-John2 and James SA Green3Abstract
Background: Cancer care is commonly managed by multidisciplinary teams (MDTs) who meet to discuss and
agree treatment for individual patients. Patients do not attend MDT meetings but recommendations for treatments
made in the meetings directly influence the decision-making process between patients and their responsible
clinician. No research to-date has considered patient perspectives (or understanding) regarding MDTs or MDT
meetings, though research has shown that failure to consider patient-based information can lead to recommendations
that are inappropriate or unacceptable, and can consequently delay treatment.
Methods: Semi-structured interviews were conducted with current cancer patients from one cancer centre who
had either upper gastrointestinal or gynaecological cancer (n = 9) and with MDT members (n = 12) from the teams
managing their care. Interview transcripts were analysed thematically using Framework approach. Key themes were
identified and commonalities and discrepancies within and between individual transcripts and within and between
patient and team member samples were identified and examined using the constant comparative method.
Results: Patients had limited opportunities to input to or influence the decision-making process in MDT meetings.
Key explanatory factors included that patients were given limited and inconsistent information about MDTs and
MDT meetings, and that MDT members had variable definitions of patient-centredness in the context of MDTs and
MDT meetings. Patients that had knowledge of medicine (through current/previous employment themselves or that
of a close family member) appeared to have greater understanding and access to the MDT. Reassurance emerged
as a ‘benefit’ of informing patients about MDTs and MDT meetings.
Conclusions: There is a need to ensure MDT processes are both efficient and patient-centred. The operationalization
of “No decision about me without me” in the context of MDT models of care – where patients are not present when
recommendations for treatment are discussed - requires further consideration. Methods for ensuring that patients
are actively integrated into the MDT processes are required to ensure patients have an informed choice regarding
engagement, and to ensure recommendations are based on the best available patient-based and clinical evidence.
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between patients and their responsible clinician.
Involving patients in decisions about their treatment is
central to UK health policy and embedded in the National
Health Service (NHS) Constitution, with the current
government using the phrase “No decision about me
without me” to describe their aspiration for the NHS [6].
In addition to an ethical rationale for patient involvement,
other benefits may include better treatment adherence,
reduced preference for major surgery, and more appro-
priate service use [7,8]. Effective involvement in decisions
requires good communication between patients and
health professionals. Interventions aimed at improving
doctor-patient communication (via patient and/or health
professional education) have been associated with a range
of positive health outcomes for patients including improved
functional status, symptom resolution and decreased
anxiety [9,10].
The terms ‘patient-centred care’ and ‘shared decision-
making’ are used liberally but lack agreed definitions
[11]. Furthermore evidence suggests clinicians are poor
at judging patients’ preferences for treatment [12] and
may have different goals to patients with regard to
shared decision-making. In a study involving 70 disease-
free rectal cancer patients and their clinicians, almost all
clinicians defined patient participation as ‘reaching an
agreement’ whereas almost a quarter of the patients
defined participation as simply ‘being informed’ [13]. A
Canadian national population-based study showed that
preferences for participation in decision-making may
vary considerably [14]. Although nearly all reported that
they wanted to be informed and offered choices, half
preferred to leave final decisions to their responsible
clinician. Being female and more educated was associ-
ated with preferring more active involvement (measured
in relation to knowledge-seeking, desire for options and
involvement in decisions).
The results from the 2011/12 UK National Cancer
Patient Experience Survey [15], completed by over 70,000
cancer patients, highlighted variable practice across dif-
ferent hospitals. Between 62-100% of patients reported
being given a choice of treatments prior to treatment
commencing, and between 56-83% of patients reported
that their views were taken account of by their team.
Nearly one in ten patients (8%) reported they did not
even know their treatment was discussed by a team.
No research to-date has considered patient perspectives
(or understanding) regarding MDTs or MDT meetings, or
how this model of working impacts on patients’ involve-
ment in the decision-making process. However, a system-
atic review highlighted that one of the key barriers to
effective decision making in MDT meetings was lack of
consideration of patient-centred information [16]. Where
such information is not at the heart of decision-makingin MDT meetings there is a risk of poor quality clinical
decisions. These may be unacceptable to the patient
and/or not clinically appropriate, which may lead to the
need for re-discussion by the MDT and consequently
may delay treatment [17-20].
This study aimed:
 To explore what current cancer patients know, and
need to know, about the MDTs involved in their care
to ensure effective involvement in decision-making.
 To examine cancer MDT members’ views on how
best to ensure that patients are meaningfully
involved in decision-making about their care in the
context of the MDT and MDT meetings.
 To gain patient and MDT members views on how
to overcome any barriers identified and improve
current practice.
Design and sample
Semi-structured interviews were conducted with current
upper gastrointestinal (upper GI) and gynaecological
(gynae) cancer patients from one cancer centre (a hos-
pital providing specialist cancer services), and with
MDT members from the teams managing their care.
Both tumour types are relatively common and include a
sizeable proportion with advanced or metastatic disease,
which in some cases require complex treatment decision-
making. Also, both tumour groups fared relatively poorly
with regard to involvement in decisions in the 2010
national patient experience survey, in which over a third
of patients treated by these teams did not feel involved in
decisions about treatment [21].
Methods
Patients were screened for eligibility by a clinical staff
member and their eligibility confirmed by the patient’s
relevant Clinical Nurse Specialist (CNS) using inclusion
and exclusion criteria (Table 1). Eligible patients were
recruited through a two-stage consent process, first being
approached by their CNS to gain consent to share their
contact details with the research team; and, if consent was
received for this, the researcher sent a detailed study infor-
mation sheet and consent form with a stamped addressed
envelope. Interviews were arranged with all consenting
patients. We recruited all eligible and consenting patients
between July-October 2012, (n = 9: 4 = gynae, 5 = upper
GI). Patients were offered either face to face or telephone
interviews (all opted for telephone interviews).
All core MDT members that had responsibility for
communicating with patients about treatment, were
emailed an invitation to participate. This included all sur-
geons, oncologists and CNS’s. Non-responders were sent a
second invite. In total 12 of the 20 eligible MDT members
participated in an interview (5 = gynae; 7 = upper GI).
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Patients Patients
• Current out-patients who have completed primary treatment for
Upper GI or Gynaecological cancer within the previous two months
• Aged 17 or under
• Unable to speak English
• Unable to cope either physically or emotionally, with the research protocol
• Able to give informed consent • Patients with major communication or cognitive problems (i.e. degenerative
illness or other condition affecting cognition and/or comprehension).
• Sufficient understanding of written and spoken English to
enable participation
MDT members
• Core MDT member
• Responsible for communication about treatment (including
Oncologists, Surgeons and Clinical Nurse Specialists)
Table 2 Characteristics of patients





Gynaecological 4 Female 68 years White British
Female 61 years White British
Female 52 years White, Australian
Female 25 years White British
Upper GI 5 Male 80 years White British
Male 75 years Black Caribbean
Male 48 years White British
Female 74 years White British
Female 61 years White British
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by telephone (n = 2).
Interviews were semi-structured, and were predomin-
antly exploratory in nature though some descriptive data
was also collected (e.g. whether or not patients had heard
of an MDT or MDT meeting, or knew their case was
discussed by a group of professionals). All interviews
lasted 30-45mins and followed a topic guide based
upon the study aims (see Additional file 1).
The protocol for this study was reviewed and granted
approval by NRES Committee East Midlands – Leicester
(Reference: 12/EM/0166).
Data analysis
Interviews were recorded digitally, transcribed and ana-
lysed using the “Framework” approach [22]. Framework
is a matrix-based approach for collating, reviewing and
understanding qualitative data. Two experienced qualitative
researchers (JFJ and CT) independently read a sample of
transcripts and discussed and agreed key themes. Due to
the a-priori interest in comparing patient and team mem-
ber’s views, two separate thematic frameworks were created
to facilitate examination of similarities and divergence
between and within patients and staff members, using
the constant comparative method. In order to maintain
anonymity, all transcripts were given unique ID pseudo-
nyms. Quotations from patients are attributed to tumour
type, whilst staff are attributed to Team A or B.
Results
Characteristics of participants
Twenty-one interviews were conducted. This included
nine patients aged 25–80 years, most from White British
ethnic origin (Table 2). At the time of interview, two
Upper GI patients were awaiting further surgery and all
others had completed treatment. Twelve MDT members
were interviewed including the MDT lead and two
CNS’ from each team together with other medical
MDT members (oncologists and surgeons, Table 3).Findings indicated that patients had limited opportun-
ities to input to or influence the decision-making process
in MDT meetings. Key potential explanatory factors that
emerged from the thematic analysis include:
1. Limited and inconsistent information provision
about MDTs and MDT meetings
2. Variable definitions of patient-centeredness (in the
context of MDTs and MDMs) by MDT members
3. The potential influence of patient knowledge about
medicine on their understanding (or recall) of
information about MDTs and MDMs
Limited and inconsistent information provision
i) What are patients told about the MDTand the MDM?
Most MDT members acknowledged that patients prob-
ably had a limited understanding about MDT/MDM’s and
that at most they might understand that recommenda-
tions for treatment were the result of an MDT discussion
between groups of different health professionals: “a panel
of experts” (Dr Jones, Team B). "I think they understand
that we meet and discuss cases but … I’m not sure they
Table 3 Characteristics of MDT members
Tumour type Total number of
interviews conducted
MDT members’ specialty/
role in the team
Gynaecological 5 MDT Lead (Gynaecologist)
2 x Clinical Oncologists
2 x Clinical Nurse
Specialists (CNS)
Upper GI 7 MDT Lead (Surgeon)
2 x Clinical Oncologist
1 x Medical Oncologist
1 x Surgeon
2 x CNS
Taylor et al. BMC Health Services Research 2014, 14:488 Page 4 of 11
http://www.biomedcentral.com/1472-6963/14/488understand the number of people involved or exactly what
we do" (Dr Smith, Team A).
Indeed a few team members described what they said
to patients about the MDT/MDM. In these examples
the information given was sparse and described pa-
tient’s as being passive receivers of information, rather
than explicitly inviting their contribution and involve-
ment: "what I say to patients about the MDT, so quite
often when there’s a difficult decision or when the treat-
ment options aren’t clear I do say to the patients we
will be discussing your case on Wednesday and then
we’ll make a decision about what we think is the best
treatment for you" (Dr London, Team A). Another
team member stated "I think every one of them that have
scans done as part of their investigation they usually
get told that … it’ll be discussed in the meeting” (Nurse
Roberts, Team A).
Although most team members stated that they at least
mentioned the MDT/MDM to patients, one doctor stated
that patients would not be interested in knowing details
about the MDT/ MDM:
"The MDT is there not to be communicated to the
patient but just to make the process safe … why does the
patient have to know this? It’s just a complication, it’s
another thing for the patient to take-in in a clinic where
they are being told all sorts of things and it’s just
another distraction and I’m not sure it’s of any rele-
vance" (Dr Drew, Team B). A similar view was shared
by another doctor from Team B who said he reserved
information for those who asked rather than offering it
to all patients:
“Patients understand that their condition will be
discussed by a panel of experts … they know those indi-
viduals will be a mixture of surgeons and oncologists,
but we don’t go into greater details than that unless
they ask … they’re interested in what the treatment
options are and what you’re going to do for them.
They’re not as interested in the process … they’re inter-
ested in outcome” (Dr Jones, Team B).ii) How are patients informed about the MDT/MDM?
MDT member’s knowledge of information resources
they could use to explain the role and membership of
the MDT to patients was variable. One doctor from
Team A mentioned a DVD resource, but nobody else from
either team mentioned this. In total, four members (2 from
each team; doctors and nurses) mentioned providing
patients with a booklet, but other members within the
same teams did not mention using this resource, although
most were aware that this was available. The information
within these booklets varied by tumour type but at most
included the team member’s names and contact details.
The majority of team members (n = 8) did not mention
using any resources in their interaction with patients;
most of whom (n = 6) reported that information about the
MDT and MDM was generally provided verbally; the
others (n = 2) stated they generally did not provide any
information, believing it to be unnecessary.
Narratives from patients reflected this unsystematic
approach to information provision. When asked what they
understood about the MDT and MDM, three patients
reported that they had not been told anything – at least
not at the time their treatment was being planned. One
patient stated that she was not told about the MDM until
she was undergoing treatment: “I think I was on my 2nd
chemotherapy” (Sarah, Upper GI patient). Three patients
discussed being given information about the MDT and
MDM verbally by their CNS, none of whom recalled
being given a booklet or any other resource. No patients
recalled being given a DVD and none specifically men-
tioned reading about the MDT in a booklet. One patient
raised the benefits of having written information: “I think
all information should be written that they’re giving
because when you are that stressed you don’t take things
in, you might take somebody with you but they might not
take it in either … at least you’ve got it in writing if you
want to know … you know you’ve got a piece of paper that
says something somewhere” (Mary, Gynaecological cancer
patient).
Some of the MDT members explicitly recognised that
patients were often overwhelmed with information at
the point of diagnosis (the point when they commonly
come into contact with their MDT). They queried how
much information patients would be able to absorb. A
nurse from Team B stated: “They actually have a little
leaflet to try to explain [the MDT] but… they get leaflets
on just about everything else so that doesn’t always get
read and absorbed” (Nurse Brown, Team B). A doctor
from the same team concurred: “patients have an increas-
ing amount of information to take in and when they come
to the clinic quite often they are literally burdened with just
reams and reams of pieces of paper … they just can’t take it
in and also the amount of information that a patient can
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[They] tend to remember the important thing you say to
them at the beginning and … the last thing that was said to
them before they leave the room. For that reason it’s quite
limited in terms of telling them about [the MDT] process
that sort of obviously directly applies to them but they don’t
necessarily have much control over, and the consultations
tend to be very factual telling them about the treatment
and why they are having that treatment and going through
the rationale and side effects and practicalities and all that
sort of thing” (Dr Jones, Team B).
When patients were able to recall who had told them
about the MDT/MDM they all reported that it was their
CNS. Four members of Team B (both CNS’ and 2 doctors)
described the importance of the CNS in relation to this
aspect of information-giving due to their level of contact
with the patient. Members of Team A generally expressed
the view that whoever saw the patient would inform them
about the MDT and MDM, rather than it being a specific
responsibility for CNS’s (or any other team member).Variable definitions of patient-centeredness
MDT members had differing views of what “patient invol-
vement” meant within the context of the MDM and the
treatment decision-making process. Some clearly articu-
lated the value of the patient being informed and actively
involved (if they wanted to be), whereas other team mem-
bers (as mentioned previously) had a view that MDTs and
MDMs were about ‘organisation’ or ‘process’ and not of
relevance to patients. Almost all team members described
shared decision-making with patients taking place after
the MDM (when treatment choices may be presented
to patients). Although most team members recognised
the value and importance of having patient-centred
information shared in the MDM, this was not described
or acknowledged as being part of a shared decision-
making process and was instead focussed on collation
of information from patients.
i) Defining patient-centredness as providing treatment
choices after the MDM
Team members who perceived that patients were
adequately involved in the treatment decision-making
process often reasoned that this was because patients
had a choice in their treatment and were given the op-
tion to agree or disagree with MDT recommendations:
"Well they are … very effectively involved in the decision
making aren’t they, we offer treatment … and suggest
treatment, so they are involved in their care … and we
alter treatment according to patient’s wishes … I say
this is what I think is the best treatment for you and if
they ask me whether there are other treatment optionsavailable I would suggest it, if those options were sensible”
(Dr Peters, Team B).
One nurse mentioned that patients were given a choice
but the specific example she gave was of a situation where
the patient was given choices only after refusing the
recommended option: “You have the odd patient who says
‘no way - I’m not having surgery’ so we explain to them
that’s fine, the other option is chemo and radiotherapy or
just radiotherapy or just chemotherapy, we will get you to
have a chat with them, that consultant, that speciality and
see what they say" (Nurse Brown, Team B).
Team members had differing views regarding the issue
of whether patients wanted choice. Some team members
recognised that patients felt overwhelmed by being given
choice about treatment: “A lot of patients don’t want to
be given a vast amount of choice – they come to see you
as a specialist because you have expertise in the area,
and they hope you will guide them into what are the best
options. But of course when they ask us questions we are
always very open and encourage them to ask questions"
(Dr Jones, Team B). In contrast another doctor from
Team B expressed his view that their practice was not as
patient-centred as he would like and that providing
choices would improve this: "I think maybe [we need to]
give options … we recommend either treatment plan A if
the patient wants very radical treatment and really
wants to go for it or treatment plan B. We could do that a
little bit more. We tend to recommend one option rather
than two or three different options" (Dr Simons, Team B).
Most patients were satisfied to leave decision making
about treatment to their doctor: “I’m happy to sort of
just go along with what’s happening, if you get what I
mean” (Christopher, Upper GI patient).
Several patients specifically commented that they were
not in a position to tell the team what they would want
to happen regarding their treatment. These patients
believed that it was better to trust the expertise of the
team: “You are not going to turn around unless you are a
doctor or a nurse or someone who knows about medical
things and argue with them. That was their decision,
they said it was the best decision and that’s the decision
they need to take to make sure that you are going to live
basically. Your life is in their hands” (Jane, Gynaecological
cancer patient). One patient understood she only had
one option for treatment: "The thing is in my case there
wasn’t any other options, it was either I had treatment or
I didn’t have treatment and that was the form of treat-
ment that they recommended but I could have refused it
obviously" (Mary, Gynaecological cancer patient).
Only one patient specifically mentioned discussing
treatment choice before the MDM. She had a preference
regarding the type of incision for surgery which she
communicated to the MDT via her CNS, who shared it
the MDM. The MDT recommendation differed from
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this she felt that the recommendation was for her bene-
fit, and that she had been actively involved in the
process: "I don’t have enough knowledge to make these
decisions for myself, [I would have preferred to] have a
horizontal [incision] though it may not have been [bene-
ficial] for me, [so] I would prefer that decision be made
on my behalf" (Lauren, Gynaecological cancer patient).
She went on to explain that it was important that pa-
tients were made aware why particular recommenda-
tions were made by the MDT: “if you are given enough
information to fully understand why it is they’ve made
this decision, the things that they’ve thought about and
dismissed… then I think it’s best to know those sort of
things”.
ii) The collection and use of patient-centred
information
Differing views and practices existed in relation to the
collection and use of patient-centred information. One
team member expressed particular dissatisfaction regard-
ing the collection and/or sharing of such information,
when occasionally some patients may be presented at the
MDM without team members having any prior knowledge
about them: "I mean there are certain recommendations
that you should make, I mean they’re common sense
recommendations anyway which is firstly that somebody
who knows the patient well is available at the MDT to
present the case and knows all the various social
circumstances, who knows the family situation, who
knows what the patient’s wishes are because if that
information is not available … we can make a decision
based on the science, we can make a decision based on
the imaging but that’s not a patient-centred decision …
for me the whole purpose of getting everyone together is
because we’re not robots and because patients do matter
and they’ve all got, they do have their opinions and they’ve
all got very different social, economic circumstances and
different religions” (Dr Simons, Team B).
A nurse from Team A felt that the quality of patient-
centred information was related to the professional group
of the team member preparing the case for discussion: “I
think that probably in most patients you could do with
more information on their social situations but I think that
is to do with whoever fills out the form and my bias would
be that the nurse specialist who fill them in probably put
in quite a bit of information as usually is our nature and I
would say that maybe junior registrars or junior doctors
may put in what they see as essential” (Nurse Roberts,
Team A).
Most of the members of Team B stated that collection
of patient-centred information was a particular responsi-
bility of the CNS and recognised the value of havingsuch information when making treatment decisions: “a
lot of the nurse specialists that report in, some of them
are extremely good at making those assessments and they
will often say to us that patients and their relatives don’t
want any active treatment, we’ve spoken to them about it
and they’re quite happy to have palliative treatment,
and that’s fine. We don’t argue any further, and the
nurse specialists on the whole will act as an advocate. It
sounds rather judicial, but on the basis on the patient’s
wishes, we do that” (Dr Jones, Team B).
Within Team A, both CNS’ discussed how they saw it
a part of their role to collect patient-centred information
and present it at the MDM: “I always feel as a CNS …
this is a really big part of my role to get the patient’s
wishes over because … I see that as a form of support"
(Nurse Roberts, Team A). However, other team mem-
bers reported that collection and presentation of such
information in the MDM should be the responsibility of
whoever refers the patient to the MDT: "it’s very much
the person that refers the patient to the MDT what
they’ve put on the form or what they say in the meeting
and that’s why it’s so important that someone is there to
know what the patient, to represent those patients wishes"
(Dr London, Team A).
Two patients (both retired healthcare professionals)
recalled being asked specific questions about themselves
which they assumed would inform decision-making
about their treatment. James stated: "Oh yes all the time
I’ve been asked these questions – who’s at home, who
looks after you, what will things be like when you are at
home and also my previous medical history … I think
they might influence what decision the MDT comes to
but again that’s entirely what you’d expect them to do
having the information made available to them" (James,
Upper GI cancer patient). Celia described how her living
conditions and caring responsibilities might impact on
the treatment decisions made: "in my case it was import-
ant because [I live in] a house with stairs and steps and
complications and an elderly husband who partly needs
looking after. So there was quite a bit of that being
thought about” (Celia, Upper GI patient).
Several patients (all without knowledge of medicine)
recalled their discussions with team members to be
solely clinically or tumour-focussed, rather than person-
focussed. Catherine stated: "No they didn’t really ask
me anything about my life, didn’t ask about children if
I remember, the only thing, at the initial interview I
had with one of the team when I was told that this is
what’s going to happen … and I said ‘oh, well I’m a
carer for my Mum’ and they said ‘you’ll have to sort
that out’, that sort of attitude, you can’t do it … have
you got somebody in mind, and I said ‘oh yes I’ve got
sisters, I’ll sort that out’” (Catherine, Gynaecological
cancer patient).
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information
One doctor from Team B felt that patient-centred data
had no place within the MDM, as the MDM was a
“technical discussion”. He felt that the clinic was the
place to make a patient-centred decision, once the
recommendation had been presented to the patient: "I
don’t personally think the [MDM] is the place to bring it
up because a number of reasons … the religious and
cultural beliefs of the person without the person themselves
are a) most likely to be misrepresented, b) pretty much
meaningless without the human being there … you’re not
managing the patient in an [MDM], you are just making a
decision on part of the information and it’s a part of the
information that needs to be analysed as a group because
ideally you want different people to look at the same infor-
mation and come to a collective decision but you don’t
need them to come to a collective decision on how this
impacts on cultural beliefs” (Dr Drew, Team B).
In contrast, other team members described the value of
having patient-centred information in the MDM, particu-
larly in relation to tailoring treatment recommendations.
A doctor from Team B stated that if patient-centred infor-
mation was not available in the MDM the recommenda-
tions they make for treatment might not be appropriate:
“If nobody in the MDT knows the patient or the notes are
not available it’s more than likely that the treatment plan
that’s recommended is not going to be the correct treatment
plan, so MDT’s can make mistakes. The MDT decision is
not necessarily the correct one” (Dr Simons, Team B).
Another doctor from Team B felt that collection and
presentation of even the smallest amount of anecdotal
information about a patient had value and really helped
to bring the case discussion “to life” within the MDM
and enabled them to personalise treatment decisions: "I
think what is very useful is some people will even use an
anecdote of what the patient said and so forth to make
the person almost appear at the MDM meeting. You
don’t need to have a two page description but if you say
this is a 72 year old bus driver … give background infor-
mation on the patient and then you can start picturing
the patient because everybody has got experience in the
MDM … So we tailor our treatment a little bit to who
we are dealing with" (Dr Reed, Team B).
A nurse from Team A described how information about
a patient’s circumstances, particularly any co-morbidities,
could be used in the MDM: "so lots of us will be very inter-
ested in their social situation … we nearly always know if
they have dementia and whether they have capacity to
make decisions themselves or whether a relative is helping
make the decisions or whether they’ve no-one at all to
make the decisions and then we need to get an advocate
in to help them to make the decision” (Nurse Roberts,Team A). A doctor from Team A acknowledged that
some clinicians discount personal circumstances from the
decision-making process in MDMs but argued against
this: “We would say at the MDM like certain things like
age and sex and religion and all these things doesn’t influ-
ence the decision but it does sometimes because if you are
85, you know, and you are a Jehovah’s Witness who won’t
have a blood transfusion … you might just think twice
about surgery” (Dr Reed, Team, B).
Both MDTs were specialist MDTs and therefore received
referrals for treatment recommendations from teams in
peripheral hospital sites. Several members from both teams
stated that decision-making was compromised when the
peripheral team omitted patient-centred information: "We
have some Trusts that don’t link in regularly and therefore
we’re discussing their patients without any knowledge at
all of the patient … we’re making decisions based on
limited information … one of the risks of that is you
could be making a recommendation that is completely
inappropriate and you assume hopefully that someone
who actually sees the patient will take the MDT decision
as it should be which is a recommendation, but not as
written in stone" (Dr Cox, Team B).
A nurse from Team A concurred with this and stated
that the process of collecting information about patients
prior to MDMs could be improved "…[the local team]
could probably say to [patients] ‘you will at some stage
be discussed in our multidisciplinary team meeting and
you may be discussed several times – is there anything
you would like [specialist team] to know about you or is
there any, have you strong religious beliefs, have you
strong wishes that you want them to adhere to or, you
know?’, so I suppose there could be that kind of thing”
(Nurse Roberts, Team A).
The potential influence of patient knowledge about
medicine on their understanding (or recall) of information
about MDTs and MDMs
A potential explanatory factor that distinguished those
with better vs. worse understanding about MDTs/MDMs
was the presence or absence of a link to medicine (e.g.
through family or their own professional background).
Three patients had such links to medicine (two were
retired healthcare professionals themselves - doctor and
a physiotherapist - and the other had a father and fiancé
who were doctors) and all were able to articulate clearly
their understanding of the function and membership of
the MDT. For example, Lauren stated: "When it was
initially thought that my MRI was suspicious I was told
that they would be having a multidisciplinary meeting
regarding me to decide the best course of action so I had
been told that this was going to happen … they did
explain to me in the meeting that these were the sort of
people who were going to be making decisions on me. It
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place … I was quite well informed from that point of
view … my understanding was that it was a team of spe-
cialists from differing branches of medicine, the radiolo-
gist who would have a look at my MRI and see exactly
what he thought of it and describe it to the surgeon …
and [involve] other specialists in that area. [This] was
my understanding of the team” (Lauren, Gynaecological
cancer patient). Lauren was also the only patient that
communicated preferences for treatment to the MDT
prior to their MDT meeting.
In contrast, patients without such links to medicine
demonstrated a much vaguer (if any) understanding of
the MDT and MDMs: “[I understood] very little really
[about the MDM] only that they would look at my case
and they would say what was the best course of action to
go … I didn’t know who could be involved apart from the
surgeon” (Catherine, Gynaecological cancer patient).
Reassurance as a benefit of informing patients about
MDTs and MDMs
“Reassurance” was a recurring theme in some MDT
member and patient transcripts. One doctor from Team
A alluded to the importance of informing patients about
the MDT because it would be reassuring to know that
their treatment plan arose from a team discussion: "Well
I mean I think the more information they have about our
processes the better really. I don’t think there’s anything
wrong about them knowing what we do, we don’t do any-
thing wrong, it’s all in their benefit so no I think it would
be good information to provide in that we have MDM’s
and all the patients are discussed … I think it would be
good that they know that that happens” (Dr Smith, Team
A). A nurse from the same team shared this view about
the benefit of ensuring patients understood the process:
"I think they would feel more empowered if they thought
there were a lot of people involved in the decision" (Nurse
Roberts, Team A).
Some patients’ narratives concurred with this. Catherine,
despite stating that she did not know anything much about
the meeting or who the team were stated: "They said they
will look at all the scans and they will assess the situation
… so I did know there was a team looking at it. And I was
reassured because obviously they do this all the time,
and they would know" (Catherine, Gynaecological cancer
patient). Another (a retired physiotherapist) stated: “A
multidisciplinary team is always a good thing, it’s
amazing, it makes a hell of a difference to have access
to the other disciplines straight away so it would have to
be a good thing" (Celia, Gynaecological cancer patient).
A nurse from Team A discussed how patients would
be reassured to know that someone they had already
met would be involved in making a treatment decision:
"They sometimes want to know who is going to be there [atthe MDM] so if there is a particular surgeon that they
knew from before, and we’re talking about maybe possibil-
ity of surgery they will ask ‘is my surgeon going to be
there?’, and actually I quite often volunteer that infor-
mation if I’m feeding back from what we discussed"
(Nurse Grant, Team A). One patient described the impact
of having this information; she was reassured by knowing
which team member was involved in making the decision
on her behalf: “He was the one face that you saw that you
knew he was in control of it all” (Jane, Gynaecological
cancer patient).
Team members and patients recommendations for
changes to current practice
Recommendations for changes to current practice were
suggested by team members and patients. These recom-
mendations focused on improving communication and
information provision, and collection and use of patient-
centred information. Team members’ recommendations
for improved communication ranged from inserting a
simple sentence in discussions: “something should be in
the guidelines when we give people information about
their treatment, to the effect that all treatment decisions
will be made by multidisciplinary team review but I
don’t think it needs any more than that really" (Dr Peters,
Team A), through to a focus on encouraging patients to
be actively involved in decision-making, though still with
a focus on post-MDM: "The MDT will decide on this or
this on your behalf and you of course have an option to
come back on that again and say that I’m not happy
with the MDM decision and maybe the patient should be
informed that they can possibly disagree with the MDM
decision and say I don’t want the MDM to decide, I want
to decide that and so the MDM can be advising me but
not deciding on my behalf” (Dr Reed, Team B).
Team members also shared recommendations for im-
proving the collection and use of patient-centred infor-
mation. One stated that there should always be someone
present in the MDM that has met the patient where pos-
sible; and another suggested that a minimum dataset
that includes patient-centred information should be used
(especially from peripheral teams): "what we’re trying to
do is say look, unless you fill in the minimal dataset which
will also include things like that, and co-morbidities, other
medical issues … we won’t discuss the patient. The prob-
lem is obviously ethically it becomes very difficult if a
patient’s very ill and needs treatment, and you’re saying,
you haven’t ticked this box so we’re not discussing it, it
gets a bit tricky” (Nurse Grant, Team B).
Recommendations from patients included a focus on
actively involving patients prior to the MDM by providing
an easy way to communicate their preferences or wishes
regarding treatment to an advocate prior to MDM. One
patient suggested that patients could be given a form to
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questions for the team?’ or…‘anything you would like to
be brought up on your behalf?’… maybe where [patients]
could just get what they want to say across and be sure
that it was relayed and spoken on their behalf” (Lauren,
Gynaecological cancer patient). one patient suggested
that they should have an opportunity to ask questions
about their treatment prior to treatment commencing,
suggesting this had not happened in her case: "Once
they made a decision on what they’re going to do with
you then I think that’s a good opportunity to sit down
with the patient again and say this is what we’re going
to do… it’s probably good to sit down then and tell you
exactly what you’re going to have before you go into the
major surgery just to ask a few more questions like do
you really need to take my ovaries, what are the reasons
why you have to take them. There could be another
opportunity there to make sure that the patient has
answered as many, all the questions that they need before
the surgery" (Jane, Gynaecological cancer patient).
Discussion
Patients had limited opportunities to input to or influence
the decision-making process in MDT meetings. This
appeared to be explained at least in part by a combin-
ation of limited and inconsistent information provision,
and variable attitudes of health professionals regarding
the importance of considering patient-centred information
in MDT meetings.
To our knowledge there has been no previous research
that has examined patients’ knowledge and understanding
of MDTs or MDT meetings. The qualitative design of this
study was not intended to produce generalizable findings
but instead to examine in detail the viewpoints of patients
and health professionals in a small number of teams in
order to generate understanding and hypotheses that
could be further tested in subsequent research. Resources
limited the length of time for recruitment of patients: in-
terviews with a broader spectrum of patients in relation to
gender, age, ethnicity and disease status would have been
beneficial and should be a focus for future research.
Some of the key findings that warrant further exam-
ination include first, the potential influence of prior
knowledge of medicine. Previous research has shown that
demographic characteristics such as gender (being female)
and education (being more highly educated), as well as
disease severity influence the extent that patients desire
active involvement in decisions about their care [14,23].
The educational status of patients is unknown for the
participants in this study but it may be that the finding
regarding knowledge of medicine is instead explained by
education status. Also we cannot know whether those that
were able to articulate a clearer understanding of MDTs
and MDT meetings were provided with more informationthan other patients (for example perhaps by asking more
questions), and/or were able to understand or recall it
more easily than other patients. Unpicking this would re-
quire an ethnographic observational approach where both
information provision and understanding are assessed.
Second, this study highlighted that health professionals
have wide ranging views regarding the patient-centredness
of the decision-making process in the context of MDTs
and MDT meetings. This directly influenced the commu-
nication they had with patients about MDTs/MDMs. In
view of the impact of lack of patient-centred information
on implementation of recommendations [17-19] and in
line with the aspiration of the current government for
‘no decision about me without me’ it is important to
address this and ensure – where possible –that patients
are informed about MDTs in a way that allows them to
actively engage with the decision-making process should
they wish to. The public inquiries following significant
failures of care within the NHS in recent years (e.g. in
Alder Hey [24] and Mid Staffordshire [25]) have rein-
forced this imperative, and the need to embed shared
decision-making into the NHS as opposed to passive
consent [26]. Shared-decision making in the context of
MDTs requires careful consideration. A survey of over
2000 cancer health professionals in the UK found that
the majority felt it was neither desirable nor practical to
include patients in MDT meetings [27]. Typically, each pa-
tient is only discussed for a few minutes (a colorectal cancer
study reported 4.5mins average [28]), requires frank and
disinhibited consideration of treatment options, and uses
medical and technical terminology that would be at best in-
comprehensible, and at worst frightening to many patients.
This does not however preclude ensuring that patients are
adequately informed about the way that decisions or rec-
ommendations will be made and given an opportunity to
engage in the process, e.g. by providing any information
they wish to be taken into account, should they wish to.
There are a number of challenges associated with this,
not least the pressures of adhering to national targets for
reduced waiting times (between diagnosis and treatment)
meaning that MDT discussions may often happen before
patients are even aware of their diagnosis, let alone had
time to consider their preferences or factors they would
want taken into account when treatments are considered.
Undertaking holistic needs assessments [29] at appropri-
ate time points along the pathway of care, and ensuring
that sharing of such information is prioritised in MDT
meeting discussions is likely to improve the patient-
centredness of the decision-making process. The CNS has
a major role in relation to this as they will often be the
team member assessing the holistic needs and acting
as the patient’s keyworker [30]. However, research has
shown that nurses may often contribute minimally in
MDT meetings [31], which may at least in part be due
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disease-focused rather than person-focused approach [20].
In addition to ensuring effective mechanisms for obtain-
ing information from patients, there is a need to develop
effective ways of supporting patients to make informed
decisions about participating in decision-making. In this
study we found that information provision about MDTs
and MDT meetings was limited and inconsistent. Col-
laborative design methodologies such as Experience
Co-Based Design [32] could be used to work with
patients and staff to design and develop information
aids and interventions (e.g. patient and health professional
education) to ensure effective communication between
health professionals and patients regarding the way deci-
sions are made. Patient decision aids have been developed
and shown to be effective at improving knowledge and
patient involvement in other health contexts, including
prostate cancer screening [8,33] and should be examined
for application in the context of the MDT.
A particular issue regarding patient-centredness in
decision-making by specialist MDTs was raised in this
study. Guidelines for best practice support recommend
that MDT discussions always include at least one person
that has met the patient [34]. The barriers and facilitators
for ensuring that this can happen, especially in exchanges
between local and specialist teams, should be urgently
examined. Patients felt reassured when they knew that
decisions were made by collectively by a team, and in
particular when they knew their clinician would be part
of that team; a finding also echoed in a recent study
with prostate patients [35].
Conclusions
Patients had limited knowledge of MDTs or opportunities
to input to MDT meeting discussions. Advances in know-
ledge about cancer have led to increasing complexity with
regard to diagnosis and treatment of the disease, and thus
reinforce the imperative for a multidisciplinary approach to
its management. There is a need to ensure MDT processes
are both efficient and patient-centred. The operationaliza-
tion of “No decision about me without me” in the context
of MDT models of care requires further consideration.
Methods for ensuring that patients are actively integrated
into the MDT processes are required to ensure patients
have an informed choice regarding engagement, and to
ensure recommendations are based on the best available
patient-based and clinical evidence.
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